 A new COVID vaccine trial will begin this fall with funding from a federal initiative at the U.S. Department of Health and Human Services. A Georgia-based company will start testing a nasal vaccine. The Phase 2B clinical trial will evaluate the effectiveness and safety of its new vaccine compared to an FDA-approved mRNA vaccine currently used to fight against the illness.